Stocks · News reference
- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone – - For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster at the American Association for
Following an FDA approval of a second-line pancreatic cancer treatment, Immuneering Corporation reaffirmed its focus on first-line metastatic pancreatic cancer patients. The company is enrolling patients in its Phase 3 MAPKeeper 301 trial evaluating atebimetinib combined with chemotherapy. Previous Phase 2a data showed 17.3-month median overall survival with manageable side effects, with 84% of patients maintaining or gaining weight at three months.
Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. See what analysts say about LYEL, IMRX, and RNA.